Charles River Laboratories International, Inc. (NYSE:CRL – Get Free Report) EVP Shannon Parisotto sold 5,046 shares of the stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $263.00, for a total transaction of $1,327,098.00. Following the sale, the executive vice president directly owned 4,807 shares in the company, valued at $1,264,241. This trade represents a 51.21% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Charles River Laboratories International Stock Performance
Shares of NYSE:CRL traded up $5.01 during trading on Thursday, reaching $265.73. 1,306,837 shares of the company’s stock traded hands, compared to its average volume of 926,372. The stock has a market capitalization of $12.80 billion, a P/E ratio of -70.67, a price-to-earnings-growth ratio of 2.61 and a beta of 1.38. Charles River Laboratories International, Inc. has a 12 month low of $144.26 and a 12 month high of $268.00. The company has a 50 day moving average of $211.45 and a 200-day moving average of $188.38. The company has a debt-to-equity ratio of 0.90, a current ratio of 1.36 and a quick ratio of 1.03.
Charles River Laboratories International (NYSE:CRL – Get Free Report) last issued its earnings results on Wednesday, August 5th. The medical research company reported $3.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.77 by $0.25. The firm had revenue of $1 billion for the quarter, compared to analysts’ expectations of $977.20 million. Charles River Laboratories International had a negative net margin of 4.59% and a positive return on equity of 15.36%. Charles River Laboratories International’s revenue was down 2.7% on a year-over-year basis. During the same quarter last year, the company posted $3.12 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. On average, equities analysts expect that Charles River Laboratories International, Inc. will post 11.05 EPS for the current year.
Hedge Funds Weigh In On Charles River Laboratories International
Key Charles River Laboratories International News
Here are the key news stories impacting Charles River Laboratories International this week:
- Positive Sentiment: JPMorgan upgraded CRL to “overweight” and raised its price target to $310 from $180, implying additional upside and signaling increased confidence in the company’s earnings recovery and demand outlook. Benzinga
- Positive Sentiment: Second-quarter results exceeded Wall Street expectations: adjusted earnings were $3.02 per share versus the $2.77 consensus, while revenue of approximately $1.0 billion topped estimates of $977.2 million. The earnings beat helped support the stock’s advance. Charles River Laboratories Q2 Earnings and Revenues Surpass Estimates
- Positive Sentiment: CRL raised its 2026 outlook to EPS of $11.15–$11.45 and revenue of roughly $3.9 billion, both ahead of analyst expectations. It also increased projected free cash flow to $400 million–$420 million. Charles River 2026 Outlook
- Positive Sentiment: Management cited improving biotech demand, stronger drug-discovery order trends and anticipated margin benefits from cost reductions and divestitures. The Discovery and Safety Assessment business reportedly has a healthy backlog and book-to-bill ratio. Charles River Lifts Profit Forecast
Analyst Ratings Changes
Several brokerages have weighed in on CRL. Evercore reaffirmed an “outperform” rating on shares of Charles River Laboratories International in a research report on Wednesday. CLSA cut shares of Charles River Laboratories International from an “outperform” rating to a “hold” rating and set a $219.00 price objective on the stock. in a report on Monday, July 20th. Sanford C. Bernstein set a $250.00 price objective on Charles River Laboratories International in a research report on Wednesday, July 1st. Weiss Ratings raised Charles River Laboratories International from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, July 1st. Finally, Barclays reaffirmed an “overweight” rating and set a $300.00 target price on shares of Charles River Laboratories International in a report on Wednesday. Twelve analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Charles River Laboratories International currently has an average rating of “Moderate Buy” and a consensus price target of $244.19.
Get Our Latest Report on Charles River Laboratories International
About Charles River Laboratories International
Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.
Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.
Read More
- Five stocks we like better than Charles River Laboratories International
- Sandisk Just Delivered a Blowout Quarter—Here’s Why the Stock Is Falling
- 4 Oil and Gas ETF Plays as Prices Stay Sky-High
- What Tesla Stands to Lose If It Walks Away From China
- Disney Sets Up for a Magical Year in 2027
Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.
